迈瑞展区内人头攒动，启元大模型、瑞影、瑞检等系列产品正进行现场演示，工作人员讲解产品特性， 吸引了众多观众咨询交流；西门子医疗展区内，几台磁共振成像设备静静陈列，专业讲解员围绕设备的 临床应用场景、影像清晰度提升等核心优势展开介绍，让观众近距离感受高端医疗装备的科技魅力。 一批AI药械、手术机器人领域的产品引人关注。精锋医疗展示了其自主研发的多孔腔镜手术机器人、 单孔腔镜手术机器人、支气管镜手术机器人等丰富完整的产品组合，并为观众演示精细的手术画面。粒 影科技发布的AI+药械研发公共服务平台，深度融合"AI蛋白质结构预测与设计""AI底盘细胞改造"等多 项自研核心技术，可将传统需数年的研发周期缩短至数月。 药械产值1576亿元 12月18日，2025深圳国际高性能医疗器械展暨创新医药展在深圳会展中心举行。此次展会设置了医学影 像及放疗、医学检验、应急救治及康复、人工智能及机器人、创新医药、供应链等"8+1+1"十大展区， 吸引了300余家全球医药与医疗器械领域的领军企业和机构参展，展示千余件创新产品，涵盖高端医疗 器械、创新药、生物制造、AI+药械、消费医疗、核心零部件等深圳乃至国内药械领域的最新成果，为 医 ...

12月18日临近收盘，医药多个细分板块表现强势。其中，百分百表征A股医疗器械板块的医疗器械指数ETF（159898）盘 中上涨0.93%；按照资金实时流入数据和净值计算，该ETF今日盘中已获得超2200万资金净买入。 具体成份股来看，迪安诊断涨8.65%，安必平涨超7%，三诺生物涨超6%，健尔康、奕瑞科技涨超4%，金域医学、贝瑞基 因、鱼跃医疗等多股涨超3%。 | | 医疗器械指数ETF159898 | | +1.12% 20日 5E | -2.33% | | --- | --- | --- | --- | --- | | | | | 60日 -10.67% 120日 +4.82% | | | | 0.544 +0.005 +0.928% | | 年初至今年4.41% 250日 52周島県 054652国島低 0 539 | -1.27% | | 委比 +32.10% | | 78941 实时 | 田阿 | 能回 | | 5 | 0.548 | | 31 OCC FGV | 10000 | | 卖4 | 0.547 | 6321 | 42.00万 手数 | | | | | | 金额 | | | B | 0.5 ...

临床上3.0T磁共振设备的磁场强度相当于地球磁场的6万倍，在磁共振环境中做手术是世界性难题。如今，来自南 开大学的交叉学科团队，正在将这一科幻电影场景变为现实。他们研发的"核磁兼容脑神经穿刺手术机器人"，能 够在术中磁共振成像（iMRI）系统的实时导航下，操控手术器械以亚毫米级的精度，穿越复杂脑组织，直达病灶 所在。这意味着医生能在手术过程中借助实时的脑区"地图"，动态避开重要功能区和血管结构，让患者的治疗更 彻底、损伤更小。在生命禁区上演的这场的"舞蹈"中，每一毫米的推进都关乎着生命…… ...

ERCP 手术机器人专家临床反馈 20251215 摘要 中国 ERCP 手术量快速增长，2024 年接近 40 万例，但仅占实际需求的 10%，预计 2030 年可达 80-100 万例，市场潜力巨大。医生缺口显著， 现有医生仅占需求量的 10%，手术机器人有望缩短学习曲线，从 200 例以上降至 100 例甚至几十例。 ERCP 机器人旨在解决传统手术的痛点，如减少医护人员的射线暴露和 疲劳，实现操作均质化，并缩短医生学习曲线。虽然初代机器人手术时 间与传统操作相近，但减少了对助手数量和技能的要求，降低了人力资 源投入。 ERCP 机器人远程操控功能将极大推动其在基层医院的普及，未来装配 5G/6G 后，可实现远程手术，为偏远地区提供技术支持。目前全球范围 内仅少数公司推出成品 ERCP 手术机器人，市场竞争格局初现。 ERCP 机器人的耗材采用开源设计，降低病人经济负担，可使用任何公 司的常规耗材。医院对采购 ERCP 手术机器人的接受度取决于产品实际 需求，作为刚需技术，具有较高优先级，若能显著提高效率和效果，医 院会考虑投入采购。 Q&A ERCP 手术在临床中主要面临哪些技术难点和痛点？ ERCP ...

12月15日，中国证监会国际合作司发布《关于深圳市精锋医疗科技股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书》。精锋医疗拟发行不 超过31,880,500股境外上市普通股并在香港联合交易所上市。该公司49名股东拟将所持合计295,880,748股境内未上市股份转为境外上市股份，并在香港联合 交易所上市流通。 招股书显示，精锋医疗致力于设计、开发及制造手术机器人。精锋多孔腔镜手术机器人MP1000为公司建议核心产品，而精锋单孔腔镜手术机器人SP1000为 关键在研产品。 根据弗若斯特沙利文的资料，公司是中国首家已完成多孔及单孔腔镜手术机器人关键性临床试验的公司。MP1000及SP1000均已具备通过绿色通道进行国家 药监局有关创新医疗（002173）器械的快速审查资格。公司于2022年12月获得国家药监局对MP1000用于泌尿外科手术的注册批准。中国手术机器人市场竞 争激烈。于最后可行日期，公司于中国有五家公司的多孔腔镜手术机器人获批，惟单孔腔镜手术机器人均未获批。 ...

智通财经APP获悉，12月15日，中国证监会国际合作司发布《关于深圳市精锋医疗科技股份有限公司境外发行上市及境内未上市股份"全流通"备案通知 书》。精锋医疗拟发行不超过31,880,500股境外上市普通股并在香港联合交易所上市。该公司49名股东拟将所持合计295,880,748股境内未上市股份转为境外 上市股份，并在香港联合交易所上市流通。 招股书显示，精锋医疗致力于设计、开发及制造手术机器人。精锋® 多孔腔镜手术机器人MP1000为公司建议核心产品，而精锋® 单孔腔镜手术机器人 SP1000为关键在研产品。 根据弗若斯特沙利文的资料，公司是中国首家已完成多孔及单孔腔镜手术机器人关键性临床试验的公司。MP1000及SP1000均已具备通过绿色通道进行国家 药监局有关创新医疗器械的快速审查资格。公司于2022年12月获得国家药监局对MP1000用于泌尿外科手术的注册批准。中国手术机器人市场竞争激烈。于 最后可行日期，公司于中国有五家公司的多孔腔镜手术机器人获批，惟单孔腔镜手术机器人均未获批。 ...

Group 1 - Medtronic's Hugo™ robotic-assisted surgical system has received FDA approval for use in urological surgeries, marking a significant entry into the U.S. market [1][2][8] - The Hugo RAS system is approved for minimally invasive urological procedures, including prostatectomy, nephrectomy, and cystectomy, with approximately 230,000 such surgeries performed annually in the U.S. [2][9] - Medtronic plans to expand the application of the Hugo RAS system to other surgical specialties beyond urology, including general and gynecological surgeries [2][10] Group 2 - The U.S. is the largest surgical robotics market globally, with a market size of $4.6 billion in 2020, accounting for 55.1% of the global market [2][12] - Intuitive Surgical's da Vinci surgical system has dominated the market since its FDA approval in 2000, with Q3 2025 revenue of $2.51 billion, a 23% year-over-year increase [3][11] - Medtronic's Hugo system, which has been in development since 2019 and received CE certification in 2021, is now positioned to compete directly with the da Vinci system in the U.S. market [4][12] Group 3 - The Chinese surgical robotics market, while currently smaller than the U.S. market, shows significant growth potential, with a market size of $318.4 million in 2020 projected to reach $2.3153 billion by 2026, reflecting a compound annual growth rate of 39.2% [4][12] - Recent financing activities in the Chinese market indicate strong investor interest, with companies like Ruijian Surgical and Agile Medical securing substantial funding [5][13] - The competition in the surgical robotics market is intensifying, with multiple players vying for market share [6][14]

又一国产手术机器人公司，要 IPO 了。 证监会官网显示，北京术锐机器人股份有限公司（以下简称：术锐机器人）已在北京证监局完成 IPO 辅导备案登记，辅导机构为中信证 券。 来源：证监会 据公开资料，术锐机器人是一家由上海交通大学徐凯教授创立的高科技医疗器械企业，致力于单孔微创腔镜手术机器人系统的研发、生 产和商业化。 更为值得一提的是，继微创机器人于 2021 年正式登陆港交所后，早在 2023 年，精锋医疗、思哲睿、和华瑞博等多家国产手术机器人企 业就展开过一次上市潮，其中也包括术锐机器人，后者同中信证券签署上市辅导协议，也正式启动 A 股 IPO 进程。 只不过，时至今日，各家还尚未成功登陆二级市场，而术锐机器人亦以二次辅导揭开了新的 IPO 征途。 交大教授带队，做出一家领军企业。 这一技术基础亦成为了徐凯于 2014 年创办术锐机器人，并研发拓展出一系列关键技术与核心部件，全面进入了产业化的根基。 据悉，依托 " 对偶连续体机构 " 这一革新性设计，术锐机器人产品所搭载的高性能可形变手术臂动作不仅灵动精准，综合性能比肩国际 顶尖的单孔手术机器人水平，还一举打破国外多年技术垄断。 术锐机器人官网显示， ...

Core Viewpoint - Beijing Shurui Robot Co., Ltd. is preparing for an IPO, having completed the IPO guidance filing with the Beijing Securities Regulatory Bureau, with CITIC Securities as the guiding institution [1][3]. Company Overview - Founded on November 5, 2014, by Professor Xu Kai from Shanghai Jiao Tong University, Shurui Robot focuses on the research, production, and commercialization of single-port minimally invasive surgical robot systems [2][5]. - Xu Kai directly holds 22.74% of the company's shares and controls an additional 31.84% through various partnerships, totaling 54.58% of voting rights [2][8]. Industry Context - The company is part of the domestic surgical robot sector, which has seen a wave of IPO attempts following the successful listing of MicroPort Robotics in 2021 [3][4]. - Shurui Robot is recognized as a leading startup in the surgical robot field, with Xu Kai having nearly 20 years of experience in this domain [5][6]. Technological Advancements - The company has developed a series of key technologies and core components, including a revolutionary design known as the "deformable dual-continuum mechanism," which enhances the performance of its surgical robots [6]. - Shurui Robot's single-port laparoscopic surgical robot became the first in China to pass the special review process for innovative medical devices in 2020 and received approval from the National Medical Products Administration (NMPA) in June 2023 [7]. Market Position and Financing - The company has completed six rounds of financing from 2019 to 2023, attracting notable venture capital firms such as Shunwei Capital and Medtronic [8]. - As of April 2025, Shurui Robot has filed over 805 patents globally, establishing a comprehensive intellectual property protection system [7].

Core Viewpoint - In 2024, MicroPort Robotics faced significant challenges due to its own R&D and commercialization struggles, compounded by governance issues at its parent company. However, changes in the parent company's shareholding structure and the potential of its equipment and consumables business model have led to a resurgence in the company's stock performance [1]. Stock Performance - MicroPort Robotics experienced two significant price surges in 2024, with the stock reaching a high of 33.70 HKD, marking a maximum increase of 252.14% [2]. - Following the peak on October 8, the stock price fell to 21.20 HKD by November 21, representing a decline of 37.09% from its high [2]. - Investor sentiment shifted from divergence to consensus, with Hong Kong Stock Connect funds reversing their previous buying and selling strategies to accumulate shares during the downturn [2][8]. Technical Analysis - The stock's price movement in September showed a strong upward trend, with a nearly 40% increase driven by a "three consecutive days of gains" pattern, leading to a significant increase in trading volume [3]. - The Bollinger Bands (BOLL) indicated a breakout from previous trading ranges, with the stock showing a "six consecutive days of gains" pattern, establishing a steep upward channel [3]. - Despite the recent volatility, the distribution of shares remains concentrated at lower price levels, suggesting potential support for future price movements [3]. Volume and Market Sentiment - The stock's price increase was accompanied by declining trading volumes, indicating a lack of buying momentum, which is typically seen as a bearish signal [5]. - As the stock price fell below key technical levels, trading volumes decreased significantly, reflecting a shift in investor sentiment from active selling to cautious observation [7]. Institutional Activity - Recent trading data indicates that Hong Kong Stock Connect funds have begun to accumulate shares, contrasting with their previous selling behavior during the stock's earlier price increases [8][10]. - Over the past 60 days, these funds have been net sellers, but recent trends show a shift towards buying as the stock stabilizes [10]. Financial Performance - MicroPort Robotics reported a total revenue of 176 million HKD for the first half of 2025, a year-on-year increase of 77%, driven by significant growth in overseas markets [13]. - The company has improved its cost management, resulting in a 59% reduction in net losses during the same period [13]. - Following positive financial results, Morgan Stanley has raised its target price for MicroPort Robotics, reflecting confidence in the company's growth potential [14].